- Innovative biologic prefilled syringe approved in EU December 13, 2024
- Legislative milestone for UK clinical trials December 12, 2024
- Pharmapack Europe 2025: Eco barrier packaging to launch December 11, 2024
- ASH 2024: CAR T-cell therapy demonstrates durable benefit in lymphoma December 10, 2024
- £16 million to fund UK-Switzerland life sciences research December 9, 2024
- Early promise for novel breast cancer immunotherapy December 6, 2024
- Recent Biologics Deals December 13, 2024
- Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2024-2025 December 9, 2024
- Biocon Announces FDA Approval of Ustekinumab Biosimilar December 7, 2024
- Update on Pending Denosumab BPCIA Litigations December 4, 2024
- European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar November 27, 2024
- Centene lobbies Trump administration to preserve Medicaid, ACA following ‘tragic’ year December 13, 2024
- CHS to sell North Carolina hospital for $280M December 13, 2024
- MedPAC supports add-on payments for low-income Medicare patient care December 13, 2024
- CareTrust REIT continues acquisition spree with $97M deal December 12, 2024
- Democrats question Oz over Medicare Advantage advocacy, UnitedHealth stock December 12, 2024
- ASTP finalizes pared down HTI-2 interoperability rule December 12, 2024
- Consumers who delayed choosing health insurance cite concerns with Trump administration: survey December 11, 2024
- New bipartisan legislation would force insurers, PBMs to sell pharmacy businesses December 11, 2024
- Who Will Pay for Prescription Drugs in 2032: Four Takeaways from the New Government Forecasts (rerun) December 13, 2024
- White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill (rerun) December 12, 2024
- Follow the 340B Prescription Dollar: How PBMs Profit from 340B Contract Pharmacies (rerun) December 11, 2024
- PBM Power: The Gross-to-Net Bubble Reached $334 Billion in 2023—But Will Soon Start Deflating (rerun) December 10, 2024
- Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun) December 9, 2024
- Four Revelations from Minnesota’s First 340B Transparency Report December 3, 2024
- Drug Channels News Roundup, November 2024: Employers & Their PBMs, Medicaid vs. 340B, U.S. Drug Prices, and Dr. G Shops for Health Plans November 25, 2024